GLP-1 analogs administered as a subcutaneous injection are being extensively studied in clinical trials for the treatment of NAFLD and are a promising therapeutic approach used in mono- or combination therapies. The gene discussed is GLP1R; the disease is metabolic dysfunction-associated steatotic liver disease.